DMDG 51st Open Meeting 2025.
September 1, 2025

We’re delighted to share that Martin Barrett, our Head of Business Development, and Rob Jenkins, our Bioanalytical Scientist, will be attending the 51st Open Meeting 2025.


This event is a fantastic opportunity to connect with industry leaders, share insights and build new collaborations. 

Martin and Rob are looking forward to meeting fellow attendees, exchanging ideas and exploring ways to create impactful partnerships that advance drug discovery and development.


🤝 If you’re attending, don’t hesitate to reach out they’ll be happy to connect, discuss your projects, and explore potential synergies.

DMDG 51st Open Meeting 2025

#Pharmidex #DrugDiscovery #DrugDevelopment #Collaboration #OpenMeeting2025

February 17, 2026
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
February 11, 2026
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
More Posts